327 related articles for article (PubMed ID: 27207533)
1. Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α.
Chen X; Zhang F; Gong Q; Cui A; Zhuo S; Hu Z; Han Y; Gao J; Sun Y; Liu Z; Yang Z; Le Y; Gao X; Dong LQ; Gao X; Li Y
Diabetes; 2016 Jul; 65(7):1904-15. PubMed ID: 27207533
[TBL] [Abstract][Full Text] [Related]
2. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
[TBL] [Abstract][Full Text] [Related]
3. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.
Finck BN; Gropler MC; Chen Z; Leone TC; Croce MA; Harris TE; Lawrence JC; Kelly DP
Cell Metab; 2006 Sep; 4(3):199-210. PubMed ID: 16950137
[TBL] [Abstract][Full Text] [Related]
4. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
6. Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.
Hinds TD; Hosick PA; Chen S; Tukey RH; Hankins MW; Nestor-Kalinoski A; Stec DE
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E244-E252. PubMed ID: 28096081
[TBL] [Abstract][Full Text] [Related]
7. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.
Huang J; Jia Y; Fu T; Viswakarma N; Bai L; Rao MS; Zhu Y; Borensztajn J; Reddy JK
FASEB J; 2012 Feb; 26(2):628-38. PubMed ID: 22009939
[TBL] [Abstract][Full Text] [Related]
8. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.
Li Y; Wong K; Giles A; Jiang J; Lee JW; Adams AC; Kharitonenkov A; Yang Q; Gao B; Guarente L; Zang M
Gastroenterology; 2014 Feb; 146(2):539-49.e7. PubMed ID: 24184811
[TBL] [Abstract][Full Text] [Related]
9. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.
Purushotham A; Schug TT; Xu Q; Surapureddi S; Guo X; Li X
Cell Metab; 2009 Apr; 9(4):327-38. PubMed ID: 19356714
[TBL] [Abstract][Full Text] [Related]
12. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver.
Mooli RGR; Rodriguez J; Takahashi S; Solanki S; Gonzalez FJ; Ramakrishnan SK; Shah YM
Cell Mol Gastroenterol Hepatol; 2021; 12(2):585-597. PubMed ID: 33798787
[TBL] [Abstract][Full Text] [Related]
14. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 represses peroxisome proliferator-activated receptor alpha and inhibits fatty acid oxidation.
Kamarajugadda S; Becker JR; Hanse EA; Mashek DG; Mashek MT; Hendrickson AM; Mullany LK; Albrecht JH
Oncotarget; 2016 Jul; 7(30):47674-47686. PubMed ID: 27351284
[TBL] [Abstract][Full Text] [Related]
16. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
[No Abstract] [Full Text] [Related]
17. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.
Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK
Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177
[TBL] [Abstract][Full Text] [Related]
18. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.
Zhang H; Shen WJ; Cortez Y; Kraemer FB; Azhar S
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G72-86. PubMed ID: 23104557
[TBL] [Abstract][Full Text] [Related]
19. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.
Hashimoto T; Cook WS; Qi C; Yeldandi AV; Reddy JK; Rao MS
J Biol Chem; 2000 Sep; 275(37):28918-28. PubMed ID: 10844002
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.
Yao L; Cao B; Cheng Q; Cai W; Ye C; Liang J; Liu W; Tan L; Yan M; Li B; He J; Hwang SH; Zhang X; Wang C; Ai D; Hammock BD; Zhu Y
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G527-G538. PubMed ID: 30789748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
